ResMed Inc. (NYSE:RMD) Shares Sold by Vinva Investment Management Ltd

Vinva Investment Management Ltd reduced its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 58.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,615 shares of the medical equipment provider's stock after selling 12,288 shares during the period. Vinva Investment Management Ltd's holdings in ResMed were worth $1,977,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. True Wealth Design LLC grew its position in ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 110 shares during the period. OFI Invest Asset Management purchased a new stake in shares of ResMed during the 4th quarter worth about $39,000. BankPlus Trust Department purchased a new stake in shares of ResMed during the 4th quarter worth about $44,000. Rosenberg Matthew Hamilton acquired a new stake in ResMed during the 4th quarter worth approximately $54,000. Finally, SBI Securities Co. Ltd. purchased a new position in ResMed in the fourth quarter valued at approximately $67,000. 54.98% of the stock is owned by institutional investors and hedge funds.

ResMed Stock Performance

RMD stock traded down $1.51 during mid-day trading on Tuesday, reaching $221.40. The company had a trading volume of 1,060,170 shares, compared to its average volume of 958,894. The stock's 50-day simple moving average is $234.76 and its two-hundred day simple moving average is $238.83. The stock has a market capitalization of $32.52 billion, a P/E ratio of 26.14, a P/E/G ratio of 1.53 and a beta of 0.74. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. ResMed Inc. has a one year low of $172.19 and a one year high of $263.05.

Remove Ads

ResMed (NYSE:RMD - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Research analysts anticipate that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th were given a dividend of $0.53 per share. The ex-dividend date of this dividend was Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a yield of 0.96%. ResMed's dividend payout ratio (DPR) is presently 25.03%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on RMD shares. The Goldman Sachs Group initiated coverage on shares of ResMed in a research report on Thursday, January 16th. They set a "buy" rating for the company. Needham & Company LLC restated a "hold" rating on shares of ResMed in a report on Friday, January 31st. StockNews.com raised shares of ResMed from a "hold" rating to a "buy" rating in a research report on Tuesday. Morgan Stanley assumed coverage on shares of ResMed in a report on Wednesday, March 19th. They set an "overweight" rating and a $280.00 price target for the company. Finally, UBS Group raised shares of ResMed from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, ResMed currently has an average rating of "Moderate Buy" and a consensus target price of $246.83.

Insider Transactions at ResMed

In related news, insider Kaushik Ghoshal sold 9,745 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the transaction, the insider now owns 9,725 shares in the company, valued at $2,327,289.75. This represents a 50.05 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the sale, the chief executive officer now owns 455,472 shares in the company, valued at $107,842,105.44. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,940 shares of company stock valued at $9,164,385. 0.71% of the stock is currently owned by corporate insiders.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.